newsfilter
← Latest News
Business Wire·

Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

ATHENA study evaluating Rubraca® (rucaparib) monotherapy versus placebo (ATHENA-MONO) in first-line ovarian cancer maintenance treatment successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: